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Abstract 
 
Effects of antiarrhythmic drugs upon the threshold delivered energy (TDE) and threshold peak 
current (TPC) for electrical ventricular defibrillation by damped sinusoidal shocks were 
investigated in 25 pentobarbital-anesthetized dogs. TDE and TPC were increased by the three 
antiarrhythmic drugs tested. Bolus injections produced a transient rise, and continuous infusions 
produced a steady rise in defibrillation threshold. The maximal percent elevations in mean 
defibrillation threshold during the 60 minutes after intravenous drug treatment in groups of n = 5 
dogs were: 
 
Treatment      % increase in TDE % increase in TPC 
Lidocaine bolus (3 mg/kg)       48    26 
Lidocaine (0.5 mg/Kg/min)       99    45 
Quinidine bolus (50 mg/Kg)     172    70 
Diphenylhydantoin (1 mg/Kg/min)      83    35 
Controls          1      4 
 
Accordingly, individuals receiving antiarrhythmic drugs whose hearts nonetheless fibrillate may 
require greater electric shock strength for defibrillation. 
 
Key words: ACLS, advanced cardiac life support, cardiac arrest, fibrillation, resuscitation 
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Introduction 
 
The minimum electrical "dose" in terms of either current or energy required to defibrillate the 
ventricles is defined as the ventricular defibrillation threshold. Although there are many reports 
of the influence of antiarrhythmic drugs on fibrillation threshold, there are no quantitative studies 
that have shown the effects of such drugs on the minimum energy or current required to 
defibrillate the ventricles. This paper describes a new phenomenon, the elevation of ventricular 
defibrillation threshold by three antiarrhythmic drugs. 
 
Drug effects upon defibrillation threshold are of potential clinical importance because patients 
who fibrillate may have been placed on maintenance antiarrhythmic drug therapy or admitted to 
coronary care units where antiarrhythmic drugs may be given routinely. A population of patients 
especially prone to sudden death may be identified [1, 2], for whom some authors have proposed 
prophylactic treatment with procaine amide or related drugs in selected cases [3, 4]. Intravenous 
lidocaine by bolus injection or continuous infusion is currently recommended for hospitalized 
patients following acute myocardial infarction in order to prevent ventricular fibrillation [5, 6]. 
Nonetheless, the ventricles of patients receiving lidocaine may still fibrillate [7]. During 
cardiopulmonary resuscitation a variety of drugs may be given prior to defibrillation. 
 
Since some authors have indicated that present commercial defibrillators, which store 400 Watt- 
seconds of energy, may have marginal or inadequate output for heavyweight patients [8, 9], the 
question of whether antiarrhythmic drugs alter the electrical dose required for defibrillation 
becomes especially pertinent. Accordingly, the present study was conducted to determine if 
antiarrhythmic drugs alter ventricular defibrillation threshold in a stable animal model. 
 
 
Methods 
 
Twenty-five mongrel dogs, weighing 6 to 12 kilograms, and anesthetized with pentobarbital 
sodium (30 mg/kg, intravenously) served as subjects. This anesthetic was chosen because we 
have previously shown that it does not alter the defibrillation threshold [10]. The details of 
anesthesia and monitoring have been described previously [11]. In brief, fibrillation was induced 
by 60 Hz electrical stimulation of the right ventricle via an intracardiac catheter-electrode. 
Defibrillation threshold was determined by repeated trials of fibrillation and transchest 
defibrillation, with successive shocks from a damped sinusoidal defibrillator (Capacitance 16 
microfarads; inductance 44 millihenrys; internal resistance 7 ohms) each shock of peak current 
amplitude 10 percent less than the amplitude of the preceding shock. The lowest shock intensity 
able to achieve defibrillation, and differing no more than 10 percent in amplitude from an 
intensity that did not defibrillate, was defined as threshold. 
 
The ventricles never were permitted to fibrillate more than 30 seconds prior to defibrillation and 
never were refibrillated until arterial blood pressure had returned to a stable level. The peak 
voltage and peak current for each shock were recorded on a storage oscilloscope. Only data from 
the first shocks applied after the onset of ventricular fibrillation were used in the calculation of 
threshold. Delivered energy was calculated from the product of peak voltage, peak current, and 
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defibrillator constants as previously described [12]. The antiarrhythmic drugs used in this study 
were quinidine gluconate injection, U.S.P. (Lilly), 80 mg/ml; lidocaine hydrochloride injection 
(Astra), 20 mg/ml, pH 6-7; and 5-5 diphenylhydantoin sodium salt (Sigma Chemical Co., St. 
Louis, Mo.). A freshly prepared, alkaline solution of diphenylhydantoin in water was used 
because the usual commercial diluent has been shown to alter the threshold for electrical 
stimulation of cardiac tissue [13]. Quinidine was given as a single intravenous bolus (50 mg/kg) 
to five dogs. Lidocaine was given as single intravenous bolus (3 mg/kg) to five dogs and as a 
constant infusion (0.5 mg/kg/min) to another five dogs. Diphenylhydantoin was given as a' 
continuous infusion (1 mg/kg/min) to an additional five dogs. These antiarrhythmic drug doses 
are in the range of 0.7 to 7 times the recommended therapeutic doses for dogs [14]. Five dogs in 
a control group received no drug other than pentobarbital to determine the effect of repetitive 
trials on the defibrillation threshold. 
 
In all groups ventricular defibrillation threshold was determined at 15 minute intervals before 
and after drug treatment. The mean of three pre-drug threshold values for each animal was 
defined as 100 per cent of control and served as the reference for drug effect. 
 
 
Results 
 
 
Figure 1 shows the dramatic elevation of the threshold current and energy caused by an 
intravenous bolus of quinidine gluconate (50 mg quinidine base/kg) in five dogs. The data points 
in Figure 1 represent mean threshold energy and current ratios, which were calculated by 
dividing the individual threshold values by the average reference value for each animal. The 
period of negative time on the abscissa represents this control period. Quinidine increased 
threshold peak current by 70 per cent and threshold delivered energy by 172 per cent. The dose 
of quinidine was sufficient to cause blood pressure to fall initially from average values 
(systolic/mean/ diastolic) of 170/140/128 mmHg (high control blood pressures characteristic of 
dogs anesthetized with pentobarbital) to 95/73/60 mmHg. Thereafter the magnitude of blood 
pressure depression gradually diminished at approximately the same rate as the magnitude of 
defibrillation threshold elevation. 
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Figure 1. Effect of intravenous quinidine on ventricular defibrillation threshold in five 
dogs. The absolute threshold values corresponding to 1.00 on the vertical axes were 
0.94 Watt-sec/Kg and 1.21 A/Kg. All threshold elevations after quinidine injection are 
statistically significant (U < 11, p < 0.01) except the final data point at 187 minutes. 
Because of the difference in the standard deviations of pre-drug and post-drug data, 
the Mann-Whitney U-test of significance was used to compare post-drug values with 
the aggregate pre-drug control values in this and subsequent figures. 
 
 
Figure 2 illustrates a similar elevation of defibrillation threshold by an intravenous bolus of 
lidocaine (3 mg/kg). The maximal elevation of threshold current was 26 percent and the maximal 
elevation of threshold energy was 48 percent. The peak effect of lidocaine appeared later than the 
peak effect of quinidine. Administration of lidocaine by continuous intravenous infusion (0.5 
mg/kg/min) also caused threshold to increase steadily in another group of five dogs (Figure 3) to 
a maximum of 199 percent of control energy and 145 percent of control current after 80 minutes. 
Blood pressure fell from 158/137/117 mmHg at the beginning to 137/119/103 mmHg at the end 
of the lidocaine infusion. 
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Figure 2 (left). Effect of intravenous lidocaine on ventricular defibrillation threshold 
in five dogs. The absolute threshold values corresponding to 1.00 on the vertical axes 
were 0.83 Watt-sec/Kg and 1.16 A/Kg. The peak elevation in defibrillation threshold is 
statistically significant (U < 11, p < 0.01). 
 
 
Figure. 3 (right). Effect of lidocaine infusion on ventricular defibrillation threshold in 
five dogs. The absolute threshold values corresponding to 1.00 on the vertical axes 
were 0.67 Watt-sec/Kg and 1.00 A/Kg.  All threshold elevations after onset of the 
infusion are statistically significant (U < 14, p < 0.05). After 30 minutes of infusion 
threshold elevations are highly significant (U < 11, p < 0.01). 
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The effect of a continuous infusion of diphenylhydantoin (DPH) (1.0 mg/kg/min) is shown in 
Figure 4. This agent also caused the defibrillation threshold to increase. The increase in threshold 
was accompanied by a decrease in systolic, mean, and diastolic blood pressures from 
185/160/132 mmHg (characteristic of pentobarbital anesthesia) to 112/87/60 mmHg during the 
DPH infusion. 
 
 
 
 
 
Figure 4. Effect of diphenylhydantoin (DPH) infusion on ventricular defibrillation 
threshold in five dogs. The absolute threshold values corresponding to 1.00 on the 
vertical axes were 0.76 Watt-sec/Kg and 1.01 A/Kg. All threshold elevations after onset 
of the infusion are statistically significant (U < 11, p < 0.01). 
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Figure 5 illustrates mean threshold energy and current in the control animals that received only 
pentobarbital. These animals were studied for a longer period of time than any drug treatment 
group to evaluate the stability of the preparation. In these animals threshold energy decreased by 
about 10 percent during the first hour of testing and thereafter remained stable. Threshold current 
did not change over a period of 280 minutes, and blood pressure remained stable, indicating little 
effect of the repeated episodes of fibrillation, circulatory arrest, and defibrillation upon the 
dependent variables of this study. 
 
 
 
 
 
Figure 5. Effect of pentobarbital anesthesia only on ventricular defibrillation threshold 
in five dogs. The absolute threshold values corresponding to 1.00 on the vertical axes 
were 0.89 Watt-sec/Kg and 1.12 A/Kg. These animals served as controls. The slight, 
periodic variations in these threshold data were not reproducible in other control 
series. 
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Discussion 
 
The objective of the present studies was to establish the direction of changes in ventricular 
defibrillation threshold produced by antiarrhythmic drugs. Some individuals might believe, a 
priori, that drugs given clinically to prevent fibrillation would also make defibrillation of the 
heart easier. Others might speculate that since most antiarrhythmic drugs reduce the excitability 
of cardiac muscle, and since defibrillation is caused by depolarization of cardiac muscle, most 
antiarrhythmic drugs would elevate the defibrillation threshold. The only previous report of the 
influence of an antiarrhythmic drug upon ventricular defibrillation is that of Woolfolk and 
associates [15] who found that quinidine (10 to 60 mg/kg, intravenously) decreased the 
likelihood of successful ventricular defibrillation in dogs given transchest shocks of 30, 40, or 50 
Watt-seconds. The present studies confirm Woolfolk and colleagues' conclusion and also 
demonstrate that failure to defibrillate in the presence of quinidine may be reversed by the use of 
increased electric shock strength. 
 
In the present study, relatively large doses of three antiarrhythmic drugs were used to 
demonstrate the phenomenon that antiarrhythmic drugs may raise the defibrillation threshold. 
The doses employed, however, did not cause mean blood pressure to fall below 70 mmHg and in 
this sense were pharmacologic rather than toxic doses. Plasma levels of quinidine, lidocaine, and 
diphenylhydantoin were not obtained in this initial study; since the pharmacokinetics of animals 
subjected to repeated ventricular fibrillation and defibrillation are complex, and equilibration of 
drug between plasma and tissue compartments could not be assumed. Under the conditions in 
which the experiments were performed it is likely that any plasma drug levels that might have 
been obtained would have been falsely high or grossly out of phase with the physiologic 
response. Indeed, the peak elevation of defibrillation threshold after an intravenous bolus of 
lidocaine occurred 40 minutes after injection in intact dogs, although peak plasma levels must 
have been established within seconds. Nonetheless, the present study points toward the potential, 
practical importance of drug induced elevations in ventricular defibrillation threshold in 
situations when defibrillator output is marginal. 
 
Pantridge and associates [7], Tacker and colleagues [8], and Collins and coworkers [9] have 
reported that in patients weighing over 100 kilograms ventricular fibrillation often is not 
abolished by maximal (400 stored Watt-second) shocks from typical clinical defibrillators. In 
comparably heavyweight animals, shocks in excess of 400 Watt-seconds increased the percent 
success in defibrillation [16]. Presumably, the defibrillation thresholds of heavyweight patients 
are already close to the shock strength provided by 400 stored Watt-seconds. In such individuals 
drug induced elevations of defibrillation threshold could be lethal. 
 
There is at present controversy about the appropriate shock strength for human ventricular 
defibrillation. The shock strength required for a given percent success reported by Adgey and 
colleagues [17] and by Crampton and coworkers [18] for out-of-hospital ventricular 
defibrillation is considerably less than the shock strengths reported by Tacker and associates [8] 
for a population of hospitalized patients. One possible explanation for the discrepancy between 
these studies may be more intensive antiarrhythmic drug therapy in the hospitalized patient 
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group. Accordingly, closer attention to drug treatment is warranted in future studies of human 
ventricular defibrillation. 
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